CTI is dedicated to developing and commercializing this technology in the medical arena. While mammography is the 'gold standard' for breast cancer screening, more than one million women a year require a breast biopsy to confirm the nature of an identified tissue mass. The emotional and physical trauma suffered by these women is well documented. Women, their families, and physicians recognize the need for more accurate, non-surgical methods of differentiating malignant from benign masses. CTI has entered the final stages of FDA approval for its breast imaging system.
Physicians can look forward to a more accurate method of identifying suspicious breast masses.
Women can look forward to less fear and more life as usual. Back to top Copyright 2000. All rights reserved.